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Abstract
Re-induction of fetal genes and/or re-expression of postnatal genes represent hallmarks of pathological cardiac remodeling,
and are considered important in the progression of the normal heart towards heart failure (HF). Whether epigenetic
modifications are involved in these processes is currently under investigation. Here we hypothesized that histone chromatin
modifications may underlie changes in the gene expression program during pressure overload-induced HF. We evaluated
chromatin marks at the promoter regions of the sarcoplasmic reticulum Ca2+ATPase (SERCA-2A) and b-myosin-heavy chain
(b-MHC) genes (Atp2a2 and Myh7, respectively) in murine hearts after one or eight weeks of pressure overload induced by
transverse aortic constriction (TAC). As expected, all TAC hearts displayed a significant reduction in SERCA-2A and a
significant induction of b-MHC mRNA levels. Interestingly, opposite histone H3 modifications were identified in the
promoter regions of these genes after TAC, including H3 dimethylation (me2) at lysine (K) 4 (H3K4me2) and K9 (H3K9me2),
H3 trimethylation (me3) at K27 (H3K27me3) and dimethylation (me2) at K36 (H3K36me2). Consistently, a significant
reduction of lysine-specific demethylase KDM2A could be found after eight weeks of TAC at the Atp2a2 promoter.
Moreover, opposite changes in the recruitment of DNA methylation machinery components (DNA methyltransferases
DNMT1 and DNMT3b, and methyl CpG binding protein 2 MeCp2) were found at the Atp2a2 or Myh7 promoters after TAC.
Taken together, these results suggest that epigenetic modifications may underlie gene expression reprogramming in the
adult murine heart under conditions of pressure overload, and might be involved in the progression of the normal heart
towards HF.
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Introduction
Heart failure (HF) represents an end-stage phenotype of a
number of cardiovascular diseases, frequently anticipated by
cardiac hypertrophy, the earliest and general response of the
heart to injury or increased workload [1,2]. Epidemiological,
clinical and experimental data point out that cardiac hypertrophy
induced by pathological stimuli is maladaptive and eventually
detrimental, and therefore an early therapeutic target to prevent
HF [1,3,4].
In response to cardiac overload, changes in the gene transcrip-
tion program are required to obtain de novo synthesis of
contractile, structural or regulatory proteins [5,6], but are also
associated to the re-induction of fetal genes including Myh7, the
gene encoding for b-myosin-heavy chain (b-MHC), and the
repression of post-natal genes such as Atp2a2, the gene encoding
for sarcoplasmic reticulum Ca2+ ATPase (SERCA-2A) [7,8]. Such
gene expression reprogramming is considered a hallmark of
pathological hypertrophy and HF, and its inhibition through
different approaches in different animal models has been shown to
reduce cardiac hypertrophy and ameliorate cardiac dysfunction
[5,9]. Thus, understanding the molecular mechanisms involved in
these processes might represent an important and necessary step to
develop new therapeutic approaches for heart disease [10,11].
The impact of epigenetic mechanisms, i.e. heritable changes in
gene expression without alterations in the gene sequence, is now
emerging as a major player in cardiovascular pathophysiology
[12]. Several epigenetic modifications, including histone modifi-
cations can affect the chromosomal structure, DNA accessibility,
and in turn gene expression [13,14]. It has been previously
reported that histone acetylation is critical for the induction of
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hypertrophic changes in cardiac muscle cells by phenylephrine
[15]. Consistently, class II histone de-acetylases (HDACs) 5 and 9
exert anti-hypertrophic effects by inhibiting the expression of pro-
hypertrophic genes [16].
The presence and extent of DNA or histone methylation have
been also recently addressed in murine cardiac hypertrophy [17]
or human HF, leading to the identification of specific epigenetic
patterns in patients with end-stage HF [18,19] and the opportunity
of defining novel biomarkers of cardiovascular diseases through an
epigenetic approach [18,19]. Although these data are very
promising, the map and nature of the epigenetic changes as well
as the mechanisms leading to epigenetic alterations in failing
hearts are far to be completely elucidated.
In the present study, we hypothesized that epigenetic modifi-
cations may underlie transient and/or stable changes of the gene
expression program occurring in HF induced by pressure
overload. To test this possibility, we used a well-established mouse
model of cardiac hypertrophy and HF induced by transverse aortic
constriction, and analyzed chromatin marks at the Atp2a2 and
Myh7 promoters after one or eight weeks of pressure overload.
Materials and Methods
Animal studies
All experiments involving animals were conform to the Guide
for the Care and Use of Laboratory Animals published by the US
National Institutes of Health (NIH Publication No. 85-23, revised
1996), to the guidelines from Directive 2010/63/EU of the
European Parliament and were approved by the animal welfare
regulation of University Federico II of Naples, Italy. Wild-type
C57/BL6 mice were purchased from the Jackson Laboratory.
Male adult mice (age 8 to 9 weeks, N= 50) were included in the
study and maintained under identical conditions of temperature
(2161uC), humidity (6065%) and light/dark cycle, and had free
access to normal mouse chow.
Mouse model of pressure overload
Pressure overload was induced in wild-type C57BL/6 mice (8-
week-old; n = 26) by transverse aortic constriction (TAC) as
previously described [4]. Mice were anesthetized with an
intraperitoneal injection of 0.1 ml/kg of mixture of 50%
Tiletamine and 50% Zolazepam (Zoletil 100) and Xylazine
5 mg/kg (Sigma-Aldrich). Another group of animals underwent
a left thoracotomy without aortic constriction (SHAM, n=8).
Mice from all the groups were sacrificed one week (1w) or 8 weeks
(8w) after surgery to perform molecular analyses. At sacrifice, after
body weight (BW) calculation, mice were anesthetized as described
above, and the efficacy of the pressure overload was invasively
tested by measuring the arterial pressures in the right carotid
artery (proximal to the suture) and the left right carotid artery
(distal to the suture) or noninvasively by transthoracic Doppler
echocardiography. Only TAC animals with systolic pressure
gradients .40 mmHg were included in the study. Next, the
hearts were removed and cardiac chambers dissected to assess left
ventricular weight.
Transthoracic echocardiography
Cardiac function was non-invasively monitored by transthoracic
echocardiography using the Vevo 770 high resolution imaging
system (VisualSonics, Toronto, Canada) before the surgery and
right before termination, 1w and 8w after surgery. Briefly, the
mice were anesthetized with an intraperitoneal injection of
0.1 ml/kg of mixture of 50% Tiletamine and 50% Zolazepam
(Zoletil 100) and Xylazine 5 mg/Kg (Sigma-Aldrich), and
echocardiograms were performed with a 30-MHz RMV-707B
scanning head (Visualsonics, Toronto, Canada).
RNA extraction and real-time PCR
Total RNA was prepared using TRIzol (Invitrogen, Eugene,
OR), according to the manufacturer’s instruction. Oligo-dT first
strand cDNA were synthesized using the SuperScript VILO
cDNA Synthesis Kit (Invitrogen, Life technologies) according to
the manufacturer’s instructions. mRNA expression was deter-
mined in cardiac samples from different experimental groups by
real-time quantitative PCR (RT-PCR) using a IQ-5 Multicolor
Real-Time PCR Detection System (BIORAD). The primers used
were: b-MHC: forward 59-CGGAAACTGAAAACGGAAAG-39,
reverse 59-TCCTCGATCTTGTCGAACTTG-39; SERCA-2A:
forward 59-TCGACCAGTCAATTCTTACAGG-39, reverse 59-
CAGGGACAGGGTCAGTATGC-39; GAPDH: forward 59-
TGCAGTGGCAAAGTGGAGATT-39, reverse 59-
TCGCTCCTGGAAGATGGTGAT-39. The initial denaturation
phase was 5 min at 95uC followed by an amplification phase as
detailed below: denaturation at 95uC for 10 s; annealing at 60uC
for 30 s; elongation at 72uC for 30 s; detection at 72uC for 40
cycles.
Quantitative Chromatin Immunoprecipitation (ChIP)
assay
Protein bound to DNA was cross-linked by treating tissues of
mouse heart with 1% formaldehyde at room temperature,
stopping the reaction 10 min later by the addition of 2.5M glycine
to a final concentration of 125 mM, followed by 5 min incubation
at room temperature. The ChIP assays were performed using the
EpiQuik Tissue Chromatin Immunoprecipitation Kit from
Epigentek Group Inc. (Brooklyn, NY). Antibodies used for
Protein-DNA immunoprecipitation were: anti-FBXL11 (KDM2A;
Novus Biologicals, Littleton, CO, USA), anti-dimethyl- H3K36
(H3K36me2; Millipore Corporation, Billerica, MA, USA), anti di-
methyl-H3K9 (H3K9me2: Millipore Corporation, Billerica, MA,
USA), anti tri-methyl-H3K27 (H3K27me3; Upstate Biotechnolo-
gy, Dundee, UK), anti-MeCp2 (Abcam Inc., Cambridge, MA,
USA), anti-DNMT1 and anti-DNMT3b (Abcam Inc., Cambridge,
MA, USA), and normal mouse IgG as a negative control antibody.
DNA from these samples was subjected to quantitative PCR
analyses, using Power SYBR Green PCR Master Mix (Life
Technologies Corporation, Carlsbad, California) in a Chromo4
Real Time thermocycler (BIORAD, London, UK). Amplification
of the Atp2a2 promoter fragment was performed using the
primers: forward 59-AGCCAAGGACACCAGTGC-39 (position
from 2547 nucleotides to 2530) and reverse 59-GGGATA-
GAGCGCGGAGTT-39 (position from 2422 nucleotides to 2
405) amplifying a 143 bp fragment. For amplification of the Myh7
promoter fragment the following primers were used: forward 59-
ACGACCTCCGGATCTGAGT-39 (position from 275 nucleo-
tides to 257) and reverse 59-GCGCGCGCTCTTATATAGTT-
39 (position from 234 nucleotides to 215) amplifying a 61 bp
fragment. The quantitative PCR conditions were: 95uC for 10 min
followed by 40 cycles of 95uC for 15 s, 62uC for 1 min. All PCR
signals from immunoprecipitated DNA were normalized to PCR
signals from non-immunoprecipitated input DNA. Non-immune
Serum or IgG (Mock) was the negative control for the non-specific
pull-down of DNA during immunoprecipitation, and provided a
measurement of the background or noise for the ChIP system.
Results are expressed as percentage (%) of the input with the
method described previously [20]. Calculations take into account
the values of at least three independent experiments.
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Statistical analysis
Data are expressed as mean 6 standard deviation (SD).
Comparisons between 2 groups were performed using the
unpaired Student t test. Multiple comparisons were made by 2-
way analysis of variance (ANOVA) or by 1-way ANOVA with
Bonferroni correction and Dunnett’s post-test. For all analyses, a
minimum value of p,0.05 was considered significant; when
present, a p value,0.01 was specified. All the analyses were
performed with GraphPad Prism version 5.01 (GraphPad
Software, San Diego, CA).
Results
Gene expression reprogramming in pressure
overload-induced heart failure
To investigate the mechanism(s) involved in left ventricular (LV)
gene expression re-programming during cardiac hypertrophy and
failure, we analyzed a well-known murine model of cardiac
pressure overload induced by transverse aortic constriction (TAC)
[4] at two time points: one week (1w) or eight weeks (8w) after
surgery, and we focused our study on two representative genes,
Atp2a2 and Myh7, whose reprogramming in cardiac hypertrophy
and failure is well established [1]. As expected, TAC mice showed
a marked increase in LV mass and a significant reduction in LV
function, as shown by increased LV weight to body weight (BW)
ratio (LVW/BW), and decreased percent fractional shortening
(FS%) compared to SHAM (Table S1 in File S1). LV samples from
both 1w and 8w TAC mice were characterized by significantly
increased expression of b-MHC (Figure S1A in File S1), while
SERCA-2A levels were markedly reduced (Figure S1B in File S1).
Chromatin changes at the Atp2a2 and Myh7 gene
promoters in pressure overload-induced heart failure
To further investigate whether epigenetic mechanisms may
mark gene expression reprogramming occurring in the progression
of the normal heart towards HF, we analyzed several different
chromatin marks associated with transcriptional activation or
repression at the Atp2a2 and Myh7 gene promoters. First, we
analyzed the well-established mark of active state, H3 di-
methylation (me2) at lysine (K) 4 (H3K4me2) at Atp2a2 and
Myh7 gene promoters in SHAM or TAC mice. Chromatin
immunoprecipitation analysis (ChIP) demonstrated in both 1w
and 8w TAC hearts a remarkable decrease of this mark at the
Atp2a2 gene promoter, while a significant increase of H3K4me2
at the Myh7 promoter was observed in 8w TAC (Figure 1, A–B).
Conversely, as repressive chromatin marks, we analyzed H3 di-
methylation at K9 (H3K9me2) and H3 tri-methylation (me3) at
K27 (H3K27me3), and found increased levels of both markers at
Atp2a2 promoter. In contrast, at Myh7 promoter, decreased
H3K9me2 and H3K27me3 were observed (Figure 1, C–F). Thus,
both repressive and activating chromatin modifications at Myh7
and Atp2a2 genes were consistent with the observed gene
expression changes (Figure S1 in File S1).
Recruitment of epigenetic writers, readers and erasers at
Atp2a2 and Myh7 gene regulatory regions in TAC hearts
The epigenetic dynamics at the Atp2a2 and Myh7 gene
promoters were analyzed in further detail, by testing a potential
recruitment of epigenetic modifying factors. The first analysis was
performed on the histone lysine-specific demethylase 2A
(KDM2A), previously shown to be responsible for the mainte-
nance of the unmethylated state of dense CpG islands [21]. In fact,
KDM2A may demethylate H3 dimethylation at K36
(H3K36me2), thus preventing the recruitment of DNA methyl-
transferases to genomic CpG islands. ChIP experiments demon-
strated that KDM2A was displaced from Atp2a2 promoter after
8w of pressure overload (Figure 2A). Consistently, H3K36me2
levels were significantly increased in 8w TAC ventricles at the
Atp2a2 promoter (Figure 2B), while they were decreased at the
Myh7 gene promoter (Figure 2C). ChIP experiments also
Figure 1. Chromatin modifications at the Atp2a2 and Myh7 gene promoters in murine heart failure. ChIP experiments were performed
at the Atp2a2 or Myh7 gene promoters using anti-dimethyl-H3K4 (H3K4me2; A and B), anti-dimethyl-H3K9 (H3K9me2; C and D) and anti-trimethyl-
H3K27 (H3K27me3; E and F) antibodies. Each experiment was repeated at least three times, and the quantitative PCR analyses were performed in
triplicate. The data are presented as percentages (%) of input DNA (mean 6 SD; *p,0.05 vs. SHAM; **p,0.01 vs. SHAM; n= 4–6 hearts/group).
doi:10.1371/journal.pone.0106024.g001
Figure 2. Recruitment of KDM2A and anti-dimethyl-H3K36 (H3K36me2) at Atp2a2 and Myh7 gene promoter regions in TAC hearts.
ChIP experiments were performed using antibodies indicated in each panel: A KDM2A; B–C anti-dimethyl-H3K36 (H3K36me2). Each experiment was
repeated at least three times, and the quantitative PCR analyses were performed in triplicate. The data are presented as percentages (%) of input DNA
(mean 6 SD; *p,0.05 vs. SHAM; **p,0.01 vs. SHAM; n = 4–6 hearts/group).
doi:10.1371/journal.pone.0106024.g002
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demonstrated that DNA cytosine-5-methyltransferase 1 (DNMT1)
and 3b (DNMT3b) were significantly recruited at the Atp2a2
promoter in both 1w and 8w TAC hearts (Figure 3, A and B),
while they were reduced at the Myh7 gene promoter (Figure 3, C
and D). In addition, the methyl CpG binding protein 2 (MeCp2),
which may be part of the chromatin repressive complex, was
recruited 8w after TAC at the Atp2a2 promoter (Figure 3E), while
it was significantly reduced in 8w TAC hearts at the Myh7 gene
promoter (Figure 3F). Based on these results, a schematic
representation of the molecular events underlying the epigenetic
transition of the Atp2a2 gene promoter under conditions of
pressure overload is presented in Figure 4.
Discussion
In the present study we demonstrate that transcriptional
reprogramming of Atp2a2 and Myh7 genes in pressure over-
load-induced cardiac hypertrophy and failure is associated with
significant epigenetic changes, modifying chromatin dynamics at
the promoter regions of these crucial genes. These results suggest
that specific chromatin conformational changes might be crucially
involved in the progression of the normal heart towards heart
failure.
Cardiac hypertrophy requires gene expression reprogramming
to promote de novo synthesis of contractile and structural proteins,
and usually promotes a ‘‘fetal’’ gene expression program. Since the
fetal gene program has been consistently linked to adverse cardiac
remodeling, both in humans and in mouse models [22,23],
molecular events that track gene expression re-programming could
serve as useful clinical biomarkers of HF progression and as novel
potential therapeutic targets.
Several epigenetic modifications, including acetylation, methyl-
ation, phosphorylation, ubiquitination, and sumoylation of histone
proteins have been shown to modify chromosomal structure and
DNA accessibility [13]. Among these, DNA and chromatin
modifications orchestrated by DNMTs, chromatin-remodeling
complexes and histone-modifying enzymes such as HDACs and
histone acetyl transferases (HATs) have been shown to regulate
cardiac gene expression during development and in response to
pathological stimuli [12,17,24].
In recent years, histone acetylation has been largely investigated
in different experimental models of cardiac hypertrophy and
failure [12,25]. In contrast, the role of histone and DNA
methylation in the heart remains much less defined. While histone
acetylation is in general associated to an active state of the
chromatin, the effects of histone methylation may be associated
with either transcriptional activation or repression, depending on
the lysine modified and whether this residue is mono-, di- or tri-
methylated [26,27]. Indeed, while H3 di- and tri-methylation on
K9 and K27 (H3K9me2 and H3K27me3) are well established
epigenetic marks associated with closed chromatin, di-methylation
Figure 3. Atp2a2 and Myh7 promoter modifications in pressure overload-induced heart failure. ChIP experiments were performed using
antibodies indicated in each panel: A,C anti-DNMT1; B,D anti-DNMT3b; E–F anti-MeCp2. Each experiment was repeated at least three times, and the
quantitative PCR analyses were performed in triplicate. The data are presented as percentages (%) of input DNA (mean 6 SD; *p,0.05 vs. SHAM;
**p,0.01 vs. SHAM; n = 4–6 hearts/group).
doi:10.1371/journal.pone.0106024.g003
Figure 4. Molecular events underlying the epigenetic switch of the Atp2a2 gene promoter in murine heart failure. Activating
chromatin modifiers and modifications are reported in green, while repressive marks are shown in red. DNA methyl-binding proteins are yellow.
doi:10.1371/journal.pone.0106024.g004
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of H3 on K4 (H3K4me2) is associated with an active chromatin
state.
Interestingly, distinct genome-wide patterns of H3K36me3
enrichment have been identified in end-stage human HF or
normal hearts [18,28], suggesting that chromatin methylation may
represent a crucial signal in the regulation of gene expression in
the heart. Previous work has specifically suggested an involvement
of histone methylation in cardiac hypertrophy [29] and, more
recently, a global genome study has clearly shown that a specific
epigenetic signature, defined by histone acetylation and methyl-
ation, regulates the expression of a large set of genes in murine
cardiac hypertrophy [17].
Here we show that expression reprogramming of the Atp2a2
and Myh7 genes in adult murine failing hearts is associated with
remarkable, opposite epigenetic modifications at their promoter
regions. Significant changes of specific chromatin marks, including
H3K4me2, H3K9me2, and H3K27me3 were identified at both
genes promoter regions. All the observed chromatin changes were
consistent with Atp2a2 gene repression and Myh7 reactivation. In
particular, H3K27me3 may also favor the recruitment of DNA
methyltranferases and may associate with more stable changes in
the expression program [32]. Indeed, it has been shown that the
susceptibility to DNA methylation of CpG islands is strictly
dependent on K36me2 levels and recruitment of KDM2A.
KDM2A promotes K36me2 demethylation, thus specifically
erases this chromatin mark and allows CpG rich promoters to
remain non-methylated [33]. Nucleation of KDM2A at CpG
dense regions results in removal of H3K36 methylation, creating
CpG island chromatin that is uniquely depleted of this modifica-
tion [33]. Most chromatin changes at Atp2a2 and Myh7 promoter
genes identified eight weeks after TAC could also be found as early
as one week, even if early modifications have lower magnitude and
not always reach statistical significance.
Atp2a2 promoter is embedded in a very dense CpG island, and
silencing of SERCA-2A in murine HF is associated with significant
loss of KDM2A and increase of K36me2 levels. We hypothesize
that this chromatin switch at a CpG rich promoter, together with
the increase of K27me3 levels and the recruitment of DNA
methylation machinery components (DNMT1, DNMT3a and
MeCp2) may represent a ‘‘high risk’’ epigenetic state predisposing
to detrimental DNA hypermethylation of Atp2a2 gene and
consequent stable repression. In fact, hypermethylation of several
genes has been observed in end-stage human HF [28].
While other groups performed their analysis in cardiomyocytes
isolated from TAC hearts [17], in our study we investigated the
extent and role of epigenetic changes in whole TAC hearts.
Importantly, our approach suffers some limitations, mainly due to
the impossibility to distinguish between cardiomyocytes and other
cardiac cell types, especially fibroblasts that might be significantly
activated and represented in long-term pressure overload-induced
heart failure. However, the isolation and analysis of cardiomyo-
cytes from TAC hearts, while ideally representing the best
procedure to analyze epigenetic changes in this cell type, might
also produce epigenetic modifications per se, and change the
epigenetic status in comparison to the living heart. Indeed, it is
now widely recognized the epigenetic reprogramming could be
even initiated and perturbed by luminous stimuli [30] or
permanence in culture can itself modify epigenetic conditions [31].
In conclusion, this study demonstrates that specific epigenetic
modifications underlie gene expression reprogramming of Atp2a2
and Myh7 gene promoters in the adult murine left ventricles under
conditions of chronic pressure overload, and might be involved in
the progression of the normal heart towards HF. Further
investigation will be necessary to establish whether the observed
chromatin switch in HF, loss of KDM2A and enrichment of
H3K36me2 at CpG islands may represent a general mechanism
operating in the transition of gene promoters from an unmethy-
lated to a methylated state. In this case, the proposed mechanism
would be critical to identify novel potential targets and new
emerging epigenetic drugs in the therapy of HF.
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